Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Authors: Enriqueta Felip, Byoung Chul Cho, V. Gutiérrez, Adlinda Alip, Benjamin Besse, Shaolin Lü, Alexander I. Spira, N. Girard, Raffaele Califano, S.M. Gadgeel, James Chih‐Hsin Yang, Sadamu YAMAMOTO, K. Azuma, Yu Jung Kim, K.-H. Lee, Pongwut Danchaivijitr, C.G. Ferreira, Yun Cheng, Mehmet Alı Nahıt Şendur, G.-C. Chang, C.-C. Wang, K. Prabhash, Y. Shinno, Daniil Stroyakovskiy, L. Paz-Ares, Jerónimo Rafael Rodríguez‐Cid, Claire Martin, M.R. García Campelo, H. Hayashi, Danny Nguyen, P. Tomasini, Maya Gottfried, Christophe Dooms, Antonio Passaro, Martin Schüler, A.C.Z. Gelatti, Scott Owen, K. Perdrizet, S.-H.I. Ou, J.C. Curtin, J. Zhang, Michael Gormley, Tingting Sun, Amey C Panchal, Marguerite Ennis, E. Fennema, Mahesh Daksh, Seema Sethi, J.M. Bauml, S.-H. Lee - Annals of Oncology 2024 cited by 81